EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Adverse Drug Events after Kidney Transplantation

Lionel Rostaing iD, Thomas Jouve iD, Florian Terrec iD, Paolo Malvezzi iD, Johan Noble iD

Journal of Personalized Medicine · 14.12.2023 · 13 (12) · 1706

DOI: 10.3390/jpm13121706 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 14.12.2023. Verfasst von Lionel Rostaing und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, University Hospital Grenoble, 38043 Grenoble, France. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction: Kidney transplantation stands out as the optimal treatment for patients with end-stage kidney disease, provided they meet specific criteria for a secure outcome. With the exception of identical twin donor–recipient pairs, lifelong immunosuppression becomes imperative. Unfortunately, immunosuppressant drugs, particularly calcineurin inhibitors like tacrolimus, bring about adverse effects, including nephrotoxicity, diabetes mellitus, hypertension, infections, malignancy, leukopenia, anemia, thrombocytopenia, mouth ulcers, dyslipidemia, and wound complications. Since achieving tolerance is not feasible, patients are compelled to adhere to lifelong immunosuppressive therapies, often involving calcineurin inhibitors, alongside mycophenolic acid or mTOR inhibitors, with or without steroids. Area covered: Notably, these drugs, especially calcineurin inhibitors, possess narrow therapeutic windows, resulting in numerous drug-related side effects. This review focuses on the prevalent immunosuppressive drug-related side effects encountered in kidney transplant recipients, namely nephrotoxicity, post-transplant diabetes mellitus, leukopenia, anemia, dyslipidemia, mouth ulcers, hypertension, and viral reactivations (cytomegalovirus and BK virus). Additionally, other post-kidney-transplantation drugs such as valganciclovir may also contribute to adverse events such as leukopenia. For each side effect, we propose preventive measures and outline appropriate treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

NODATadverse drug eventanemiadyslipidemiahypertensionimmunosuppressionkidney transplantationleukopenianephrotoxicityviral reactivation

Autor:innen und Institutionen

  • Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, University Hospital Grenoble, 38043 Grenoble, France.
  • Institute for Advanced Biosciences (IAB), INSERM U 1209, CNRS UMR 5309, Université Grenoble Alpes, 38043 Grenoble, France.
  • Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.

ORCID-Profile: Lionel Rostaing, Thomas Jouve, Florian Terrec, Paolo Malvezzi, Johan Noble

Zitieren

APA

Rostaing, L., Jouve, T., Terrec, F., Malvezzi, P., & Noble, J. (2023). Adverse Drug Events after Kidney Transplantation. Journal of Personalized Medicine, 13(12), 1706. https://doi.org/10.3390/jpm13121706

Vancouver

Rostaing L, Jouve T, Terrec F, Malvezzi P, Noble J. Adverse Drug Events after Kidney Transplantation. Journal of Personalized Medicine. 2023;13(12):1706. doi:10.3390/jpm13121706

BibTeX
@article{Rostaing2023,
  author = {Rostaing, Lionel and Jouve, Thomas and Terrec, Florian and Malvezzi, Paolo and Noble, Johan},
  title = {Adverse Drug Events after Kidney Transplantation},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  volume = {13},
  number = {12},
  pages = {1706},
  doi = {10.3390/jpm13121706}
}
Kostenlos starten →